NEW ALLIANCE BETWEEN CLARIVATE ANALYTICS AND BIOINFOGATE TO DELIVER SAFETY & TOXICITY INTELLIGENCE TO PHARMA AND HEALTHCARE RESEARCHERS AND DECISION MAKERS

Philadelphia / Barcelona, February 28, 2019

Bioinfogate will cross-link the OFF-X translational safety intelligence portal with the Cortellis suite of solutions from Clarivate Analytics to enable enhanced insights for targets and drugs of interest

Bioinfogate, a leading healthcare data science organization, today announced it has into a global agreement with Clarivate Analytics to cross-link the OFF-X safety intelligence portal with Cortellis preclinical intelligence. In addition, Clarivate will leverage its commercial footprint to expand OFF-X usage to life science professionals who are benefiting from Cortellis, its suite of life sciences data and analytics solutions. The agreement makes it easier for customers to integrate, access and apply toxicity and adverse events intelligence across all phases of drug research and development (R&D).

Toxicity and adverse events cause more than 30% of drugs to fail during the R&D process, which costs the industry approximately $35 billion each year. OFF-X is used across pharma and biotech organizations, in leading research centers and by regulatory bodies around the world, addressing the need for new approaches to enhance early safety assessments that can reduce patient burden and avoid costly failures. Updated daily, OFF-X enables safety liabilities to be monitored and anticipated across all phases of drug R&D.

In this partnership, both organizations have also agreed to identify, develop and deploy new capabilities, including additional platform cross-linking, content syndication, and API-enabled integration to ensure interopability. Cortellis drug and target ontologies are used within OFF-X to provide platform linkages, which pave the way for enhanced data delivery.

“We are pleased to partner with Clarivate Analytics to expand and accelerate the reach of our safety and toxicology data assets,” commented Josep Prous, Jr., Executive Director, Bioinfogate. “We look forward to expanding the OFF-X value proposition by giving researchers and regulators access to complementary data, analytics and insights in Cortellis.”

“Ensuring drug safety is of vital importance to our industry, and enabling the interoperability between Cortellis and the OFF-X platform will help to advance this goal,” said Mukhtar Ahmed, President, Life Sciences, Clarivate Analytics. “Through this partnership, we’ll be able to significantly expand the reach – and utility – of critical drug efficacy and safety information to researchers around the world.”

 

About Bioinfogate
Bioinfogate is a forward-thinking, private company working to solve unmet medical needs. Our innovative data science products support the discovery and development of better and safer drugs. We are committed to building industry leading solutions and identifying and investing in emerging projects that align with our core business in the life sciences and data analytics.

Our passion and capabilities stem from more than 60 years’ experience creating and managing biomedical knowledge, first at Prous Science (1958-2007, acquired by Thomson Reuters in 2007), and then at Prous Institute for Biomedical Research. Bioinfogate is the latest initiative within the Prous Group of companies to embrace a long tradition and expertise in scientific knowledge management.

For more information visit www.bioinfogate.com

 

About Bioinfogate OFF-XTM
The Bioinfogate OFF-XTM portal provides integrated preclinical toxicity and clinical adverse event intelligence for drugs and targets in all phases of drug R&D, including first-in-class and emerging targets. OFF-X allows prompt identification of toxicology & safety signals and de-risking of R&D projects. As of February 2019, the portal covers a range of 15,000 targets and 10,000 drugs & biologics, and is populated with more than 260,000 expertly curated safety alerts and 500,000 references of interest associated to 4,000 adverse effects. OFF-X is used across pharma and biotech organizations, in leading research centers and regulatory bodies

For more information visit www.targetsafety.info

 

About Cortellis
Cortellis gives life to science by unlocking the hidden insights in data. This industry-leading solution curates the broadest and deepest sources of intelligence to enable precise, actionable answers to specific questions across the R&D lifecycle — from discovery and clinical development through regulatory submission and commercialization. By supporting data-driven decisions, Cortellis helps pharmaceutical companies, biotech and medical device/diagnostic firms accelerate innovation. In 2017, 80% of U.S. companies filing NMEs, 91% of companies achieving breakthrough therapy status and 70% of the top licensing deals were informed by Cortellis intelligence.

To learn more, visit www.Clarivate.com/Cortellis

 

About Clarivate Analytics
Clarivate Analytics is a global leader in providing trusted insights and analytics to accelerate the pace of innovation. Building on a heritage going back more than a century and a half, we have built some of the most trusted brands across the innovation lifecycle, including the Web of Science, Cortellis, Derwent, CompuMark, MarkMonitor and Techstreet. Today, Clarivate Analytics is a new and independent company on a bold entrepreneurial mission, to help our clients radically reduce the time from new ideas to life-changing innovations.

For more information, please visit www.clarivate.com.

 

Forward-Looking Statements
This press release and oral statements made with respect to information contained in this release may contain forward-looking statements regarding Clarivate Analytics. Forward-looking statements provide Clarivate Analytics’ current expectations or forecasts of future events and may include statements regarding anticipated synergies and other future expectations. These statements involve risks and uncertainties including factors outside of Clarivate Analytics’ control that may cause actual results to differ materially. Clarivate Analytics undertakes no obligation to update or revise the statements made herein, whether as a result of new information, future events or otherwise.

 

Media Contacts:
BioInfogate
info@bioinfogate.com

Clarivate Analytics
media.enquiries@clarivate.com

Download this article Clarivate and Bioinfogate partnership agreeement PR 20190225

BIOINFOGATE EXHIBITING AT THE SOCIETY OF TOXICOLOGY’S 58TH ANNUAL MEETING AND TOXEXPO IN BALTIMORE, MD (MARCH 10-14, 2019)

Feb 15, 2019

Bioinfogate will be showcasing some of their recent developments at the Society of Toxicology’s 58th Annual Meeting and ToxExpo in Baltimore, MD, March 10-14 2019.

At the exhibition (booth 4210), the latest version of our translational safety intelligence portal OFF-X will be presented, including new and forthcoming enhancements like the expansion of the Drugs&Biologics area or the launch of the Additional References section, developed in order to expand the coverage of targets in the system.

A series of case studies will be presented to demonstrate OFF-X’s utility for a wide variety of professionals including:

  • Biologists and Bioinformaticians, to perform new target safety assessment
  • Medicinal Chemists, to identify potential toxicophores and optimize hit compounds
  • Data Scientists, to build predictive and AI models using OFF-X’s high quality curated and structured dataset
  • Toxicologists and Non-Clinical Safety Researchers, to analyze data for regulatory endpoints of interest, assess secondary pharmacology and potential off-target liabilities
  • Clinical Researchers, to optimize clinical trial design, understand mechanistic toxicity of adverse events observed in clinical trials and to benchmark competitors’ safety profiles
  • Pharmacovigilance teams to discover unknown adverse events and support understanding of safety alerts
  • Regulatory professionals, to facilitate mandatory reporting requirements of regulatory bodies
  • Business Development Analysts, to enhance due diligence of potential in-licensing opportunities

Since its launch in 2017, Bioinfogate OFF-X has been providing integrated preclinical toxicity and clinical adverse event intelligence for drugs and targets in all phases of R&D, including first-in-class and emerging targets. OFF-X allows prompt identification of toxicology and safety signals and de-risking of R&D projects. As of February 2019, the portal covers a range of 7,000 targets and 9,000 drugs & biologics, and is populated with more than 260,000 expertly curated safety alerts and 500,000 references of interest associated to 4,000 adverse effects. OFF-X is used across pharma and biotech organizations, in leading research centers and regulatory bodies (for more information visit www.targetsafety.info).

For further information or to schedule a meeting during the conference, please contact info@bioinfogate.com.

 

About Society of Toxicology (SOT)

SOT, founded in 1961, is a professional and scholarly organization of scientists from academic institutions, government, and industry representing scientists who practice toxicology in the US and abroad. The Society’s mission is to create a safer and healthier world by advancing the science and increasing the impact of toxicology. The SOT Annual Meeting hosts 6,000+ participants from the fields of toxicology, safety, regulation, risk assessment and more.

 

About Bioinfogate

Bioinfogate is a forward thinking, private company working to solve unmet medical needs. Our innovative data science products support the discovery and development of better and safer drugs. We are committed to building industry-leading solutions and identifying and investing in emerging projects that align with our core business in the life sciences and data analytics.

Our passion and capabilities stem from more than 60 years of experience creating and managing biomedical knowledge, first at Prous Science (1958-2007; acquired by Thomson Reuters in 2007), and then at Prous Institute for Biomedical Research. Bioinfogate is the latest initiative within the Prous family group of companies embracing a long tradition and expertise in scientific knowledge management.

OFF-X SAFETY MAPS CONCEPT TO BE PRESENTED AT THE CHEM-BIO INFORMATICS SOCIETY (CBI) ANNUAL MEETING (TOKYO, OCTOBER 9-11, 2018)

Sep 17, 2018

Bioinfogate has been invited to speak at the Chem-Bio Informatics Society (CBI) Annual Meeting “Drug Lifecycle Management and Regulatory Sciences – Frontier of AI-driven Drug Discovery Age” which takes place in Tokyo, Oct. 9-11, 2018.

During the Focused Session FS08 “Computational toxicology – practical and application”,  (Tue Oct. 9, 16:00-17:30), Josep Prous, Jr., Ph.D., Executive Director at Bioinfogate, will present “Interactomics technologies in the discovery of emerging drug target safety issues”.

The interactome can be defined as the global biologically relevant interactions that form a highly connected network. It can be understood as a map to investigate how individual genetic perturbations (i.e. the target modulation effect of a drug) propagate through the network and impact the system as a whole.

In his presentation, Dr Prous, Jr. will introduce how the the OFF-X translational safety portal coupled to advanced methods in protein -protein interaction networks can lead to:

  • Identification of potential safety liabilities associated to new targets by analyzing the neighborhood of our target of interest,
  • Assessment of adverse events safety hotspots
  • Better understanding of mechanisms of toxicity

The OFF-X Safety Maps initiative is the first interactome-based solution which considers target safety information from early discovery to pharmacovigilance, providing a unique collection of adverse event – target/action associations.

 

For further information or to schedule a meeting during the conference, please contact info@bioinfogate.com.

 

About the Chem-Bio Informatics Society

The Chem-Bio Informatics (CBI) Society is a Japanese non-profit organization that aims to provide a platform for promoting cutting-edge interdisciplinary areas related to chemistry, biology, and informatics. The CBI Society is interested in molecular recognition and molecular modeling, in silico drug discovery, bioinformatics and its applications in medicine, information and computing approaches for drug design and ADMET studies, and emerging new technologies.

 

About Bioinfogate

Bioinfogate, a leading data science organization, is the producer of the OFF-X portal (https://www.targetsafety.info/). OFF-X is the first translational safety intelligence portal that allows drug R&D scientists to be promptly informed about the target modulating effects of small molecules and biologics leading to preclinical toxicity and clinical adverse events. Updated daily with expertly curated safety alerts, OFF-X covers more than 7,600 targets in all stages of drug R&D from emerging and first-in-class targets to targets for drugs that have reached the market.